Metformin Improves Diabetic Bone Health by Re-Balancing Catabolism and Nitrogen Disposal

Xiyan Li¹, Yuqi Guo², Wenbo Yan³, Michael P. Snyder¹, Xin Li²*

¹ Department of Genetics, Stanford University, Stanford, CA 94305–5120, United States of America, ² Basic Science and Craniofacial Biology, New York University College of Dentistry, New York, NY 10010, United States of America, ³ Department of Biology and Chemistry, Nyack College, New York, NY 10013, United States of America

* xl15@nyu.edu

Abstract

Objective

Metformin, a leading drug used to treat diabetic patients, is reported to benefit bone homeostasis under hyperglycemia in animal models. However, both the molecular targets and the biological pathways affected by metformin in bone are not well identified or characterized. The objective of this study is to investigate the bioenergetic pathways affected by metformin in bone marrow cells of mice.

Materials and Methods

Metabolite levels were examined in bone marrow samples extracted from metformin or PBS-treated healthy (Wild type) and hyperglycemic (diabetic) mice using liquid chromatography-mass spectrometry (LC-MS)-based metabolomics. We applied an untargeted high performance LC-MS approach which combined multimode chromatography (ion exchange, reversed phase and hydrophilic interaction (HILIC)) and Orbitrap-based ultra-high accuracy mass spectrometry to achieve a wide coverage. A multivariate clustering was applied to reveal the global trends and major metabolite players.

Results

A total of 346 unique metabolites were identified, and they are grouped into distinctive clusters that reflected general and diabetes-specific responses to metformin. As evidenced by changes in the TCA and urea cycles, increased catabolism and nitrogen waste that are commonly associated with diabetes were rebalanced upon treatment with metformin. In particular, we found glutamate and succinate whose levels were drastically elevated in diabetic animals were brought back to normal levels by metformin. These two metabolites were further validated as the major targets of metformin in bone marrow stromal cells.
Conclusion

Overall using limited sample size, our study revealed the metabolic pathways modulated by metformin in bones which have broad implication in our understanding of bone remodeling under hyperglycemia and in finding therapeutic interventions in mammals.

Introduction

Diabetes mellitus (DM) is a group of chronic diseases that are characterized by high blood glucose levels and are becoming a global epidemic [1]. If not controlled, DM adversely affects many tissues including bone [2], a dynamic organ that undergoes continuous remodeling to maintain its quantity and quality. Patients with diabetes are at greater risk of fractures mostly due to not only extra-skeletal factors, such as propensity to fall, but also bone quality alteration, which reduces bone strength. The balance between bone resorption by osteoclasts and bone formation by osteoblasts is critical for skeletal homeostasis [3–5]. Type-1 and Type-2 diabetes are associated with an increased risk of osteoporosis and fragility fractures [2] and osteoclastogenesis is usually enhanced and leading to accelerated bone resorption in DM [6–8].

It has been recognized that metformin, an oral anti-diabetic medicine and an insulin sensitizer, improves bone metabolism and turnover. Metformin-treated T2D patients have decreased risks of bone fracture [9]. The osteogenic effects of metformin have been documented in cellular and rodent models: 1), metformin promotes osteoblast differentiation and inhibits adipocyte differentiation in cultured rat marrow mesenchymal stem cells, likely through inhibition of PPARγ, a nuclear receptor that regulates lipid and glucose metabolism [10]; 2), metformin increases trabecular bone formation through activation of AMPK signaling in osteoblastic cells, a major intracellular pathway that senses energy starvation [11]. Conversely, metformin directly inhibits bilateral ovariectomy-induced bone loss in rats [12] and osteoclastogenesis[13], which is also evidenced by a significant reduction of serum bone resorption marker (-12.7%) in male diabetic patients taking metformin [14]. Interestingly, the osteogenic effects by metformin may be specific to diabetes as bone formation is not promoted by metformin in mice with normal blood glucose levels [15]. These observations suggest that metformin may elicit a complex mode of actions in bone maintenance, which are associated with metabolic conditions, although the causality is still unclear.

Several observations point to the role of metformin as a metabolic switch that simultaneously inhibits anabolism and activates catabolism [16–18], including: 1) AMPK activation that stimulates β-oxidation of fatty acids and ketogenesis and inhibits cholesterol and lipid synthesis; 2) inhibition of respiratory complex I that reduces both NADH consumption and the generation of endogenous ROS (1–3% of total electron transport from oxidative phosphorylation); 3) suppression of cAMP elevation that inhibits lipogenesis. These intracellular consequences of metformin administration directly counteract the effects of insulin, and may thus alleviate harmful effects resulting from elevated insulin levels in T2D. However, aside from the aforementioned observations and correction of hyperglycemia, it remains largely unclear how metformin modulates its molecular targets in a cell. Since hyperglycemia is a chronic metabolic disease, metabolic deterioration in diabetic bone marrow could be the direct and fundamental reason for compromised bone quality and quantity. It would be intriguing to investigate the metabolomic responses that mediate the osteogenic effects of metformin to reduce skeletal fracture risk under T2D conditions. To date, there have been no studies to examine the skeletal metabolic effects by metformin in diabetes.
In this study, we investigated the mechanism of metformin actions in bone maintenance in hyperglycemic (MKR, Stands for MCK-KR-hIGF-IR) and wild type mice. MKR mice rapidly develop severe diabetes due to a dominant negative mutant of human IGF1 receptor (hIGF-IR) that is specifically expressed in skeletal muscle by muscle-creatinine kinase MCK [19]. We applied an untargeted high performance liquid chromatography-mass spectrometry (LC-MS) approach which combined multimode chromatography (ion exchange, reversed phase and hydrophilic interaction (HILIC)) and Orbitrap-based ultra-high resolution mass spectrometry to achieve a wide coverage of cellular metabolites. A multivariate clustering was applied to reveal the global metabolic interactions between metformin and diabetes and pinpoint major metabolite players. The functions of these metabolites supported that metformin might target these metabolites to regulate bone homeostasis under diabetic condition.

Materials and Methods

Animals

All animal experiments were carried on with the compliance of New York University Institutional Animal Care and Use Committee (IACUC). The protocol approval number was 111004. Hyperglycemic mouse model MKR breeders were generously provided by LeRoith and colleagues [19]. By creating a dominant negative mutant of human IGF1 receptor, MKR mouse rapidly develops severe diabetes due to a decrease in glucose uptake and insulin resistance [19]. Friend Virus B (FVB) background wildtype (WT) breeders were ordered from Jackson Lab (Bar Harbor, ME).

Bone mineral density (BMD) and bone formation

Twelve-week-old male WT and MKR mice were each randomly assigned to two groups (n = 4 in each group) and received daily intraperitoneal (I.P) injections of vehicle (PBS) (HyClone, Logan, UT) or metformin (Met, 200mg/kg BW) (Calbiochem, San Diego, CA) in 50ul volume for 14-days. After euthanization, long bones from hind limbs were dissected. Paraformaldehyde-fixed femora were evaluated with μCT using a SkyScan 1172 high-resolution scanner (Bruker microCT, Kontich, Antwerp, Belgium) with 60kV voltage and 167μA current. Reconstruct cross section with 9.7 μm pixel size and scan images analyzed by using CTan (V.1.14.4) to generate the Regions of interest. CTVox was used to generate the 3D image with a 60 degree view angle and (0, 0, 4) camera position afterwards.

Metabolomics sample preparation

Total bone marrow cells were obtained by cutting both ends of long bones open and flushing out with PBS into Eppendorf Protein LoBind tubes (1.5ml). After washing twice with PBS, cells were counted the using a hemocytometer. Then 10 million of the cells were frozen immediately and reffered as frozen bone marrow cells. At the time of extraction for HPLC, frozen cells were mixed with dry ice-cool 80% methanol (mass-spec grade) (Fisher Scientific, Hampton, NH) at a ratio of 30 μL/million cells, and then quickly thawed on heat block set at 50°C for 5 min. The suspension was then processed by three rounds of 1 min vortex at max speed, chilled briefly on dry ice. The mixture was incubated at 4°C for 1 hour before centrifuge at 20,000 x g for 20 min at 4°C. The supernatant was stored at -20°C and used as metabolite extract for LC-MS analysis. For LC-MS analysis, the metabolite extract was transferred to 150 μL deactivated glass insert housed in Waters 2-ml brown MS vials (Waters Corporation, Milford, MA). Chemical standard solution was prepared from synthetic complete mixture from Sigma-Aldrich (Y1501) (St. Louis, MO, USA) at a concentration of 19 μg/ml 80% methanol (mass-spec grade).
LC-MS Acquisition

Metabolite extract was analyzed in a platform that consists of Waters UPLC-coupled Exactive Orbitrap Mass Spectrometer (Thermo Scientific, Waltham, MA), using a mix-mode OPD2 HP-4B column (4.6x50 mm) (Shodex, Showa Denko, Tokyo, Japan). The column temperature was maintained at 45°C. Five microliters of each sample maintained at 4°C was loaded by the autosampler (Fisher Scientific, Hampton, NH) in partial loop mode for three times at positive mode and negative mode, respectively. The binary mobile phase solvents were: A, 10 mM NH₄OAc in 10:90 Acetonitrile:water; B, 10 mM NH₄OAc in 90:10 Acetonitrile:water. Both solvents were modified with 10 mM HOAc for positive mode acquisition, or 10 mM NH₄OH for negative mode. The 30-min gradient for both modes was set as: flow rate, 0.1 ml/min; 0–15 min, 99% A, 15–18 min, 99% to 1% A; 18–24 min, 1% A; 24–25 min, 1% to 99% A; 25–30 min, 99% A. The MS acquisition was in profile mode and performed with an ESI probe, operating with capillary temperature at 275°C, sheath gas at 40 units, spray voltage at 3.5 kV for positive mode and 3.1 kV for negative mode, Capillary voltage at 30 V, tube lens voltage at 120 V, and Skimmer voltage at 20 V. The mass scanning used 100,000 mass resolution, high dynamic range for AGC Target, 500 milliseconds as Maximum Inject Time, and 75–1200 m/z as the scan range. The system was operated by Thermo Xcalibur v2.1 software (Thermo Scientific, Waltham, MA). All chemicals were from Sigma-Aldrich (St. Louis, MO) if not specifically mentioned.

LC-MS data analysis

The raw data files generated from LC-MS were centroided with PAVA program [20] and converted to mzXML format by an in-house R script (distribution upon request). Mass feature extraction was performed with XCMS v1.30.3 [21]. The mass features were then manually searched against the Metlin metabolite database using 5 ppm mass accuracy. Retention time matching with compounds in the standard mixture was also performed for a portion of the metabolite hits. Only those mass features with a KEGG metabolite entry were retained for further analysis. The scored mass features were then clustered with SIMCA v13.03 (Umetric). The clustering used the O2PLS-DA model and unit-variance scaling. The KEGG IDs of those metabolites with high discriminatory power for metformin treatment in hyperglycemic mice were used for pathway enrichment analysis with IMPaLA [22].

Focus network construction

The KEGG pathway enrichment listed in Table 1 were imported and merged by matching their KEGG IDs in Cytoscape (v3.2.0). Analysis of network connectivity by the number of edges in this focus network was calculated, and the node sizes and labels were formatted according to the number of edges. The focus network is presented in organic layout format in Cytoscape.

Statistic Analysis

Following a Guideline to Univariate Statistical Analysis for LC/MS-Based Untargeted Metabolomics-Derived Data [23], we performed multivariate analysis and univariate analysis to capture the overall metabolomic patterns between healthy and diabetic groups. We used multivariate analysis of manually curated high-confidence mass features. We used univariate t-test to score the potential significance. Detailed statistic analysis is included in the legend of each figure. For the rest, analysis of variance (ANOVA) was used when study subjects were more than 2 groups, followed by the Bonferroni t-test. Two-tailed student’s t-test was used to
compare the difference between two experiment groups. A value of $P < 0.05$ was considered to statistically significant.

Results

Metformin specifically alleviated the BMD reduction in MKR mice

MKR mice have slender bones and exhibit skeletal fragility and susceptibility to fracture due to reduced transverse bone accrual and increased osteoclastogenesis [24]. Our study (depict in Fig 1A) confirmed the hyperglycemia and compromised basal bone condition in MKR mice in comparison to WT (Fig 1B and 1C). Interestingly, metformin treatment significantly and specifically improved the bone quality: both the trabecular bone mineral density (BMD) (Fig 1C) and the amount of bone volume (BV/TV) of the femoral distal metaphyseal regions (Fig 1D) were elevated by metformin in MKR mice, but not in WT mice, as demonstrated by μCT 3D analysis (Fig 1E).

Metformin differentially shifts the overall bone marrow metabolite profiles between WT and MKR mice

To examine the metabolic change, we performed metabolomics profiling with LC-MS (see Methods for instrument settings and analysis procedure) using multimode chromatography (HILIC). We extracted 14062 mass features (each defined by a pair of retention time and accurate mass) from positive mode and 5959 mass features from negative mode. A total of 346 unique metabolites (229 from positive mode, 130 from negative mode) were identified after manual validation with database search and comparing with compound standards, and used in Table 1. Pathway enrichment analysis of metformin-suppressed metabolites from MKR mice.

| KEGG pathway_name | Pathway ID | Overlapping Metabolites | All Metabolites | $P_{metabolites}$ | $Q_{metabolites}$ |
|--------------------|------------|-------------------------|----------------|------------------|------------------|
| Alanine, aspartate and glutamate metabolism | KO00250 | C00158;C01042;C00022;C00025;C00026;C00232;C00042;C00122 | 28 | 7.67E-09 | 1.39E-06 |
| Citrate cycle (TCA cycle) | KO00020 | C00158;C00149;C00417;C00026;C00042;C0022;C00122 | 20 | 1.44E-08 | 2.28E-06 |
| Glyoxylate and dicarboxylate metabolism | KO00630 | C00158;C00160;C00149;C00417;C00025;C00026;C00042;C00898;C00022 | 58 | 2.60E-07 | 2.40E-05 |
| Butanoate metabolism | KO00650 | C01089;C00022;C00025;C00026;C00232;C00042;C00122 | 41 | 3.18E-06 | 0.000193 |
| Histidine metabolism | KO00630 | C00860;C02835;C00025;C00026;C00785;C05570;C00439 | 45 | 6.11E-06 | 0.000333 |
| Vitamin B6 metabolism | KO00750 | C00022;C00118;C00026;C00279;C00847;C00232 | 32 | 9.62E-06 | 0.000457 |
| Pentose phosphate pathway | KO00030 | C00117;C00022;C00118;C00279;C0022;C00121 | 35 | 1.66E-05 | 0.000735 |
| Glutathione metabolism | KO00480 | C01672;C00072;C00750;C0025;C00051;C00134 | 38 | 2.71E-05 | 0.00111 |
| Cysteine and methionine metabolism | KO00270 | C00022;C00094;C00979;C00059;C00491;C03145;C00051 | 57 | 3.05E-05 | 0.00124 |
| Arginine and proline metabolism | KO00330 | C00750;C00025;C00437;C04281;C00581;C00022;C0134;C00122 | 90 | 8.63E-05 | 0.00273 |
| Ascorbate and aldarate metabolism | KO00053 | C00072;C00800;C0022;C00191;C00026;C01620 | 47 | 9.41E-05 | 0.00295 |
| Taurine and hypotaurine metabolism | KO00430 | C00022;C00025;C00026;C00094 | 22 | 0.000377 | 0.00731 |

The KEGG IDs for all 65 metabolites with a high pQ2 score (>0.05, see Fig 2B) were used for the pathway enrichment analysis (http://impala.molgen.mpg.de/impala/impala). The Q-value cut-off were < 0.01.

doi:10.1371/journal.pone.0146152.t001
Fig 1. Metformin protected bone loss in hyperglycemic mice. A. Scheme of the experimental design in which 12-week-old male wild type (WT) and hyperglycemic (MKR) mice were treated with vehicle (PBS) or metformin intraperitoneally daily for 2-weeks. Long bones from both side hind limbs were
multivariate clustering analysis. As the clustering results showed (Fig 2A), metformin clearly altered the metabolite profiles of mouse bone marrow, as each sample groups resided tightly in discrete clusters with high statistical confidence ($R^2_Y = 0.942$, $Q^2 = 0.591$). The metabolomic changes induced by metformin exhibited similar horizontal shift (primary change) for both WT and MKR, suggesting metformin exerts similar global effects on metabolism in WT and MKR mice. However, metformin elicited additional metabolomic changes only in MKR mice, as demonstrated by the vertical shift (secondary) in the clustering plot (Fig 2B). These additional changes may explain the benefits in bone health only observed in MKR mice but not in WT mice when treated with metformin.

Metformin preferentially affects energy and nitrogen metabolic pathways

Based on the model defined by clustering in Fig 2A, the contribution of each individual metabolite was assessed for their discriminatory power, which can be approximated by their distance to each group reference placeholder (Fig 2B). As the benchmark for this clustering, metformin resided unequivocally in close proximity to both WT and MKR groups with metformin treatment (Fig 2B), supporting the validity of this analysis. Since the metabolites that resided in the upper section (quadrants I and II) in Fig 2B represent those with high discriminatory power specific to MKR only, we used arbitrary criteria ($Y$-variable > 0.05) to select 65 metabolites as high confidence variables for pathway enrichment analysis (see Methods). Given that a majority of these metabolites are suppressed by metformin (judged by their closer distance to MKR_PBS than to MKR_Met), these results suggest that metformin acts by suppressing key metabolic pathways, and preferentially targets and suppresses energy metabolism (e.g. TCA cycle) and nitrogen metabolism (e.g. urea cycle and several other amino acid pathways) (Table 1). Metformin also exacerbated the metabolomic suppression that already exists in MKR, as more metabolic pathways were suppressed by metformin in addition to those already suppressed in untreated MKR (Table 2). Pathway-wise contribution of individual metabolites also showed that both TCA cycle and arginine/proline metabolism (hosting urea cycle) were shifted away from MKR control to MKR with metformin and to WT groups (Fig 2C and 2D).

These observations provide metabolomic evidence to support several previous reports, including 1) depletion of TCA cycle by metformin in rat liver and breast cancer stem cells [25, 26], 2) increase of aerobic glycolysis and reduction of glucose metabolism by metformin through the TCA cycle in breast cancer cells [27], and 3) indirect regulation of urea cycle through metformin-mediated AMPK activation [28].

Diverse response patterns of metabolites suggest complex consequences of metformin administration

Our study also revealed a great diversity in how individual metabolites are affected by metformin (Fig 3). Interestingly, the metformin levels in MKR cells were only 71% of those in WT, suggesting the drug uptake/delivery in MKR may not be as effective as in WT. A number of metabolites that increased in MKR condition were restored to the levels in WT by metformin. Metabolites in this group include succinate, aconitate, uric acid and citrate which belong to the TCA cycle and glycolysis. These results indicate that metformin is resetting metabolic...
Fig 2. Metformin shifted metabolomics profiles of bone marrow in both wild-type and hyperglycemic mice. A. The clustering scatter plot of 345 metabolites from bone marrow cells of WT and MKR mice upon metformin (Met) or control (PBS) treatment. Each dot represents one of 3 technical replicates from each of 4 biological samples (for MKR_Met, n = 3). The clustering used the O2PLS-DA model and unit-variance scaling in SIMCA. R²Y = 0.942, Q² = 0.591. B. The scatter plot of metabolite contribution to clustering in panel A. The first and second predictive components (R² = 0.631) from the O2PLS-DA model in panel A are superimposed with their p and q plots. Each magenta dot represents a metabolite. Each blue dot represents the reference point for each sample group. The names were showed for a few metabolites with high discriminatory power between sample groups. Plots were generated in SIMCA. C-D. The scatter plot of metabolite contribution in two representative KEGG metabolism pathways (as in Fig 2B). All metabolites in the displayed pathway are showed if detected in this study regardless of their statistical significance. Metformin is always included as reference.

doi:10.1371/journal.pone.0146152.g002
pathways such as TCA cycle and glycolysis in MKR bone marrows, which could be beneficial in protection against bone damage caused by diabetic conditions.

In contrast, metformin made no substantial differences in intracellular glucose concentration between WT and MKR, as in both cases metformin suppressed intracellular glucose significantly when compared to vehicle treatment. This intracellular glucose-lowering effect by metformin may trigger starvation response that in turn leads to increased glucose uptake through facilitated translocation of glucose transporters [29].

Incremental suppression was observed for metabolites like glutamate, aspartate, fumarate, oxoglutarate, malate and lactate, whose levels were normal in WT but lowered by metformin in MKR (Fig 3). These patterns suggest that the homeostatic control of these metabolites was

doi:10.1371/journal.pone.0146152.t002

| KEGG pathway name                                      | Overlapping metabolites | All metabolites | P_{metabolites}  | Q_{metabolites} |
|--------------------------------------------------------|-------------------------|-----------------|------------------|-----------------|
| **Down regulated in MKR (N = 82)**                     |                         |                 |                  |                 |
| Glycine, serine and threonine metabolism               | 11                      | 50              | 2.10E-09         | 6.57E-08        |
| Arginine and proline metabolism                        | 11                      | 91              | 1.37E-06         | 2.32E-05        |
| Purine metabolism                                      | 10                      | 92              | 1.14E-05         | 0.000178        |
| Cysteine and methionine metabolism                     | 7                       | 57              | 0.000118         | 0.00152         |
| Alanine, aspartate and glutamate metabolism            | 5                       | 28              | 0.000196         | 0.00226         |
| Taurine and hypotaurine metabolism                     | 4                       | 22              | 0.000832         | 0.00736         |
| Nicotinate and nicotinamide metabolism                 | 5                       | 49              | 0.00273          | 0.0186          |
| **Down regulated by metformin (N = 125)**              |                         |                 |                  |                 |
| Alanine, aspartate and glutamate metabolism            | 13                      | 28              | 2.74E-13         | 1.60E-11        |
| Glyoxylate and dicarboxylate metabolism                | 14                      | 58              | 9.65E-10         | 2.17E-08        |
| Arginine and proline metabolism                        | 17                      | 91              | 1.01E-09         | 2.22E-08        |
| Glycine, serine and threonine metabolism               | 13                      | 50              | 1.47E-09         | 3.10E-08        |
| Histidine metabolism                                   | 11                      | 45              | 5.85E-08         | 1.08E-06        |
| Cysteine and methionine metabolism                     | 11                      | 57              | 7.79E-07         | 1.08E-05        |
| Citrate cycle (TCA cycle)                              | 7                       | 20              | 1.17E-06         | 1.52E-05        |
| Taurine and hypotaurine metabolism                     | 7                       | 22              | 2.44E-06         | 3.06E-05        |
| Pentose phosphate pathway                              | 8                       | 35              | 7.13E-06         | 7.58E-05        |
| Nicotinate and nicotinamide metabolism                 | 9                       | 49              | 1.27E-05         | 0.000116        |
| Glutathione metabolism                                 | 8                       | 38              | 1.37E-05         | 0.000125        |
| Butanoate metabolism                                   | 8                       | 41              | 2.48E-05         | 0.000215        |
| Oxidative phosphorylation                              | 5                       | 16              | 8.18E-05         | 0.000632        |
| Glycerophospholipid metabolism                         | 8                       | 52              | 0.00147          | 0.00105         |
| Sulfur metabolism                                      | 6                       | 29              | 0.00192          | 0.00133         |
| Choline metabolism in cancer                           | 4                       | 11              | 0.000232         | 0.0015          |
| D-Glutamine and D-glutamate metabolism                 | 4                       | 12              | 0.00034          | 0.00214         |
| Purine metabolism                                      | 10                      | 92              | 0.00426          | 0.0026          |
| Valine, leucine and isoleucine biosynthesis             | 5                       | 23              | 0.000531         | 0.00315         |
| Pyrimidine metabolism                                  | 8                       | 66              | 0.000786         | 0.00449         |
| Thiamine metabolism                                    | 5                       | 30              | 0.00189          | 0.00987         |

The KEGG IDs of metabolites that lie >0.05 unit away from y = -x in Fig 2B were used as high-confidence metabolites specific to MKR for pathway enrichment analyses with IMPaLA. Similarly, the KEGG IDS of metabolites that lie >0.05 unit away from y = x in Fig 2B were scored as high-confidence metabolites specific to metformin treatment in MKR for IMPaLA analyses. The Q-value cut-off were < 0.01 (except for “Nicotinate and nicotinamide metabolism” that is included for comparison purpose). No enrichment was found for both upregulated metabolite groups in MKR (N = 42) and in metformin treatment (N = 17). The pathways that found in both groups are in italics for the metformin-treatment group.
Fig 3. Individual metabolite levels in bone marrow affected by metformin. Each plot shows the mean ± SEM values of respective sample groups for one particular metabolite (n = 4 for WT_PBS, WT_Met, MKR_PBS, n = 3 for MKR_Met, each sample with technical triplicates). The p-values for t-test (two-tailed, unequal variance) is also showed whenever significant (< 0.05). Plots were generated in GraphPad Prism 6.

doi:10.1371/journal.pone.0146152.g003
defective in MKR mice, which was exacerbated by metformin and may arise as a consequence of the reestablished metabolic balance that is overall attenuated by metformin (e.g. ATP, see below). Phosphoenol pyruvate (PEP), in contrast, was elevated by metformin in WT but unaffected in MKR. This pattern suggests a hyper-active glycolysis pathway and corroborates increased glucose uptake by metformin [29].

Surprisingly, ATP and NAD (nicotinamide adenine dinucleotide), two metabolite benchmarks for cellular energy regeneration capacity, were greatly suppressed by metformin only in WT (Fig 3). In contrast, metformin failed to further suppress the already reduced ATP and NAD levels in MKR. These patterns indicated that the capacity of overall energy output in MKR was not further reduced by metformin, despite the observation that many related metabolites are affected. Instead, our results strongly suggest that metformin alleviates the hyperglycemic condition by modulating metabolic processes more than just energy generation.

The diversity in response patterns echoes the unexpected discovery and re-discovery of the roles metformin in medicine [2, 30–32], and might explain its elusive modes of action that is still at large after its first application in humans 70 years ago.

Network analysis pinpoints the metabolic process targets of metformin

To help pinpoint the actual metformin targets, we constructed a focused network by merging all the over-represented mouse metabolic pathways in Table 1 (Q value < 0.01) (Fig 4). The relative importance of individual nodes (metabolites or genes) was assessed by their respective connectivity (the number of edges within the network). Several metabolites emerged as the metabolite hubs for metformin response (N of edges ≥3), including glutamate, pyruvate, oxoglutarate, all of which were highly scored in this study (Fig 3) and was confirmed in BMSCs (S1A Fig). Glutamate acts as an autocrine and/or paracrine signal mediator in osteoblasts and osteoclasts to inhibits bone formation while stimulating bone resorption [33]. The function of glutamate in bone indicates glutamate as a valid metabolic target of metformin since metformin stimulates osteoblasts while suppress osteoclasts. Similarly, metformin significantly reduced the elevated succinate level in MKR bone (Fig 3) and BMSCs (S1B Fig).

Top hub genes include gamma-glutamyltransferase 1 (Ggt1), whose homozygous mutants exhibit abnormal skeletal phenotypes [34], and several others in TCA cycle including Isocitrate dehydrogenase 1 (Idh1), MDH2 malate dehydrogenase 2 (Mdh2), and glutamic-oxaloacetic transaminase 1 (Got1). These entities demonstrate the range of metformin actions in cells despite that not all of them may be the direct targets of metformin.

Discussion

As the first-line drug for T2D treatment, metformin has been widely studied and associated with several metabolic processes by clinical and experimental studies, such as enhancing glycolysis by sensitizing glucose uptake and eliminating TCA cycle flux and oxidative phosphorylation [29, 35, 36], antagonizing vitamin B12 [37] and its major metabolic target folate [38], and diverting amino acid metabolism to energy generation [34, 39, 40]. It also appears that the boost in glucose uptake by metformin is independent of insulin [29], and vitamin D (another bone strengthening nutrient) is unaffected by metformin [37]. These processes together depict the complex nature of the cellular outcome from metformin administration which is at least partially due to the basal metabolic status in the context of different tissues/cells.

Here we firstly examined the response of MKR mouse bone to metformin (Fig 1). The advantage of MKR type-2 diabetes model is that its lean phenotype could minimize the interference from other variables like obesity, because fat tissues may substantially impact on bone metabolism and homeostasis [41–43]. Our metabolomic analysis of MKR mouse reveals that
Metformin targets a wide spectrum of metabolites/pathways. In our study, the elevated levels of TCA cycle metabolites and reduced levels of ATP and NAD in hyperglycemic mice register an abnormal capability of energy regeneration which is common in diabetic conditions. This situation is marked by compensatory mobilization of catabolism from alternative energy sources (e.g. amino acids) in response to energy deficit when supply mismatches demand [44]. However, the metabolic effects accompanying the altered energy generation machinery (e.g. TCA cycle, glycolysis) may not always be desirable, especially when the burden on metabolic waste disposal (e.g. urea cycle) is greatly increased. This may jeopardize the survival of the glucose-starved cells in hyperglycemia and diabetes (such as uric acid, Fig 3) [40]. Metformin is known to indirectly activate AMPK, the starvation rescue switch to increase catabolism [17, 18]. It is therefore intriguing that metformin, a catabolism enhancer, may actually improve hyperglycemic or diabetic conditions where the catabolism is already hyper-active.

Considering that energy sources other than glucose, such as amino acids, are more frequently used in hyperglycemia or diabetes [39], concomitant disposal of nitrogen through urea cycle is under higher pressure to remove excessive nitrogen waste, which often leads to high serum uric acid levels in diabetes [45]. Early observations indicate that metformin interferes with aerobic utilization of metabolic fuels, reducing the utilization of pyruvate and glycerol and decreasing the rate of fat re-esterification [46]. We showed that although metformin elicited similar primary metabolomic changes in WT and MKR mice (Fig 2A), additional suppressions

Fig 4. Potential metabolism targets of metformin revealed in this study. KEGG metabolism pathways enriched in this study (Table 1) were merged in a focus network. The font size of each node reflects the connectivity weight (number of edges) in this focus network. Each node represents either a metabolite (circle) or a protein (square). The edges indicate directions of biochemical interactions in this network. Plot was generated in Cytoscape.
were evident only in the metabolome of MKR mice (Table 2). These metformin-specific metabolites were over-represented not only in energy pathways, but also in nitrogen recycle and amino acid metabolism (Fig 4, Table 1 and Table 2).

Our results support that in addition to activation of catabolism, metformin also enhanced on nitrogen metabolism, such as the arginine/proline metabolism pathway (urea cycle) (Table 1) to energize energy generation and detoxify metabolite waste simultaneously. It also appears that the beneficial effects of metformin on diabetic bone health derive more from detoxification rather than restoring the final energy output to normal levels, as the ATP/NAD levels were unaffected by metformin (Fig 3).

Further metabolomic pathway analysis revealed that metformin specifically suppresses metabolites in non-carbohydrate metabolic pathways such as nitrogen disposal (urea cycle), which could signify a stimulated urea cycle caused by hyperglycemia [28]. The treatment of metformin could ultimately lead to re-established metabolic balance with improved efficiency in diabetic condition.

The fact that glutamate was scored as the top hub metabolic target of metformin in the metabolomic network (Fig 4) is a strongly indicator of the validity of this metabolomic pathway analysis. Glutamate is a fundamental extracellular messenger molecule in many tissues, and is used in bone for both neural and non-neural signaling [47]. High extracellular glutamate inhibits proliferation of osteoblastic cells [48] and preferentially suppresses osteoblastogenesis than adipogenesis through the cysteine/glutamate antiporter in mesenchymal stem cells [49]. High glutamate could also stimulate osteoclastogenesis through glutamate-mediated activation of the NF-κB pathway [50]. Diabetes and even early prediabetic insulin resistance are associated with increased levels of glutamate in the circulation [51] which corroborates our observation that glutamate was elevated in MKR bone marrow (Fig 3). Therefore, the ability of metformin to significantly reduce the elevated glutamate levels in MKR mouse bone marrow and BMSCs (S1A Fig) could contribute to metformin’s protective function in diabetic bone. As glutamate is a highly connective metabolite in multiple processes including overall energy balance, redox status, and bone marrow cell differentiation, it is likely that metformin modulates malfunctioning metabolism in diabetic bone marrow that leads to restoration of elevated glutamate. In this regard, our network analysis successfully identified metabolites that have known roles in bone regulation. In addition, other hub metabolites with no known roles in bone could also guide us to identify novel key factors targeted by metformin in regulation of bone homeostasis.

Succinate, another metabolite target revealed by this network, may also regulate bone remodeling through osteoclastogenesis. Metabolically, succinate is well studied as key player in TCA cycle and electron transfer chain. However, to our knowledge, there is no report on the role of either succinate or its receptor in osteoclastogenesis up to date. Current studies on succinate-SUCNR1 signaling were limited to retinal and immune cells [52–56]. Succinate-SUCNR1 signaling leads to ERK1/2 activation and NFκB cellular translocation. Interestingly, both phosphorylated ERK1/2 [57–59] and NFκB have a crucial role in osteoclast differentiation and bone resorption [60–63]. A recent in vitro study in HEK293s cells [64] found that SUCNR1 is a Gα(i) coupled receptor that increases intracellular calcium concentrations in an inositol phosphate dependent mechanism via PLCβ activation. Calcium signal in osteoclasts has essential and diverse cellular functions including differentiation and gene transcription [65–67]. These studies indicate that SUCNR1 signaling could elicit the same pathways to regulate osteoclast migration, differentiation and function. In addition, SUCNR1 activation regulates dendritic cell migration and activity in response to succinate [55]. As dendritic cells and osteoclasts are both derived from the hematopoietic cell lineage, succinate activated SUCNR1 signaling could also regulate osteoclast migration, activity and eventually bone resorption.
Therefore, it is possible that metformin exerts its anti-bone resorption effects by inhibiting SUCNR1/succinate signaling in bones under diabetic conditions.

**Conclusion**

In conclusion, metformin specifically suppresses metabolites in other non-carbohydrate metabolic pathways such as nitrogen disposal (urea cycle), which may suggest improved efficiency that ultimately leads to re-establish the metabolic balance in type 2 diabetic condition. More specifically, glutamate and succinate could be promising mediators for the beneficial effects of metformin in type 2 diabetic bones. Although with limited sample size, our novel finding supports that metformin modulates metabolism in a multiplex manner that alleviates compromised bone metabolism in type 2 diabetics. These findings has to be further evaluated with bigger sample size.

**Supporting Information**

S1 Fig. Validation of other potential metabolism targets of metformin at cellular level in primary bone marrow stromal cells (BMSCs). Male WT and MKR mice (3-month old) were daily treated with PBS or metformin for 14 days, bone marrow flush out cells from long bones were cultured in MEM Alpha Modification (α-MEM) medium containing L-Glutamine, Ribonucleosides (HyClone, Logan, UT, USA), supplemented with 15% Fetal Bovine Serum (Atlanta Biologicals, GA, USA), 100 μg/mL streptomycin, 100 Units/mL penicillin (Gibco, Grand Island, NY, USA) in a 37°C, 5% (v/v) CO2 and humidified incubator. A week later, the culture with enriched primary BMSCs were harvested for mass spectrum analysis. Each plot shows the mean ± SEM values of respective sample groups for one particular metabolite (n = 4 for WT_PBS, WT_Met, MKR_PBS, n = 3 for MKR_Met, each sample with technical triplicates). The p-values for t-test (two-tailed, unequal variance) are showed whenever significant (< 0.05). Plots were generated in GraphPad Prism 6.

(TIF)

**Acknowledgments**

All the animal experiments conducted in this study were in accordance with Division of Laboratory Animal Resources (DLAR), and the animals were housed in Specific Pathogen Free (SPF) unit in New York University animal facility.

All of the contributors to this article have been included as co-authors and informed consent of this submission.

**Author Contributions**

Conceived and designed the experiments: Xin Li Xiyan Li. Performed the experiments: Xiyan Li YG. Analyzed the data: Xiyan Li YG Xin Li. Contributed reagents/materials/analysis tools: MPS Xin Li. Wrote the paper: Xiyan Li WY MPS Xin Li.

**References**

1. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011; 378(9785):31–40. doi:10.1016/S0140-6736(11)60679-X PMID: 21705069.

2. Yan W, Li X. Impact of diabetes and its treatments on skeletal diseases. Frontiers of medicine. 2013; 7 (1):81–90. doi: 10.1007/s11684-013-0249-9 PMID: 23377889.
3. Eriksson EF. Cellular mechanisms of bone remodeling. Reviews in endocrine & metabolic disorders. 2010; 11(4):219–27. doi: 10.1007/s11154-010-9153-1 PMID: 21188536; PubMed Central PMCID: PMC3028072.

4. Feng X, McDonald JM. Disorders of bone remodeling. Annual review of pathology. 2011; 6:121–45. Epub 2010/10/13. doi: 10.1146/annurev-pathol-011110-130203 PMID: 20936937; PubMed Central PMCID: PMC3571087.

5. Li X, Liu H, Qin L, Tamasi J, Bergenstock M, Shapses S, et al. Determination of dual effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network analysis. The Journal of biological chemistry. 2007; 282(45):33086–97. Epub 2007/08/11. doi: 10.1074/jbc.M705194200 PMID: 17690103.

6. Krakauer JC, McKenna MJ, Buderer NF, Rao DS, Whitehouse FW, Parfitt AM. Bone loss and bone turnover in diabetes. Diabetes. 1995; 44(7):775–82. Epub 1995/07/01. PMID: 7789645.

7. Suzuki K, Kurose T, Takizawa M, Maruyama M, Ushikawa K, Kikuyama M, et al. Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density. Diabetes research and clinical practice. 2005; 68(2):117–25. Epub 2005/04/30. doi: 10.1016/j.diabres.2004.08.006 PMID: 15860239.

8. Takizawa M, Suzuki K, Matsubayashi T, Kikuyama M, Suzuki H, Takahashi K, et al. Increased bone resorption may play a crucial role in the occurrence of osteopenia in patients with type 2 diabetes: Possible involvement of accelerated polyol pathway in its pathogenesis. Diabetes research and clinical practice. 2008; 82(1):119–26. Epub 2008/09/09. doi: 10.1016/j.diabres.2008.07.008 PMID: 18774197.

9. Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia. 2005; 48(7):1292–9. PMID: 15909154.

10. Gao Y, Xue J, Li Y, Jia Y, Hu J. Metformin regulates osteoblast and adipocyte differentiation of rat mesenchymal stem cells. J Pharm Pharmacol. 2008; 60(12):1695–700. PMID: 19000376. doi: 10.1111/j.0022-3578.2008.012017.x.

11. Shah M, Koia B, Bataveljic A, Arnett TR, Viollet B, Saxon L, et al. AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass. Bone. 2010; 47(2):309–19. PMID: 20399918. doi: 10.1016/j.bone.2010.04.096.

12. Gao Y, Li Y, Xue J, Jia Y, Hu J. Effect of the anti-diabetic drug metformin on bone mass in ovariec-tomized rats. Eur J Pharmacol. 2010; 635(1–3):231–6. PMID: 20307352. doi: 10.1016/j.ejphar.2010.02.051.

13. Mai QG, Zhang ZM, Xu S, Lu M, Zhou RP, Zhao L, et al. Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats. Journal of cellular biochemistry. 2011; 112(10):2902–9. doi: 10.1002/jcb.23306 PMID: 21618954.

14. Zinman B, Haffner SM, Herman WH, Holman RR, Lachin JM, Kravitz BG, et al. Effect of rosiglitazone, metformin, and glyburide on skeletal gene expression in vivo by microarray and network analysis. The Journal of endocrinology and metabolism. 2010; 95(1):134–42. Epub 2009/10/31. doi: 10.1210/jc.2009-0572 PMID: 19875477.

15. Jeyabalan J, Viollet B, Smitham P, Ellis SA, Zaman G, Bardin C, et al. The anti-diabetic drug metformin does not affect bone mass in vivo or fracture healing. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2013; 24(10):2659–70. Epub 2013/05/07. doi: 10.1007/s00198-013-2371-0 PMID: 23644877; PubMed Central PMCID: PMC3777188.

16. Hardie DG. Sensing of energy and nutrients by AMP-activated protein kinase. The American journal of clinical nutrition. 2011; 93(4):891S–6. Epub 2011/02/18. doi: 10.3945/ajcn.110.001925 PMID: 21325438.

17. Hardie DG. AMPK: a key regulator of energy balance in the single cell and the whole organism. Int J Obes (Lond). 2008; 32 Suppl 4:S7–12. Epub 2008/09/18. doi: 10.1038/ijo.2008.116 PMID: 18719601.

18. Hardie DG. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology. 2003; 144(12):5179–83. Epub 2003/09/10. doi: 10.1210/en.2003-0982 PMID: 12960015.

19. Fernandez AM, Kim JK, Yakar S, Dupont J, Hernandez-Sanchez C, Castle AL, et al. Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes & development. 2001; 15(15):1926–34. doi: 10.1101/gad.908001 PMID: 11485987; PubMed Central PMCID: PMC312754.

20. Guan S, Price JC, Prusiner SB, Ghaemmaghami S, Burlingame AL. A data processing pipeline for mammalian proteome dynamics studies using stable isotope metabolic labeling. Molecular & cellular
proteomics: MCP. 2011; 10(12):M111 010728. doi: 10.1074/mcp.M111.010728 PMID: 21937731; PubMed Central PMCID: PMC3237081.

21. Smith CA, Want EJ, O’Maille G, Abagyan R, Siuzdak G. XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Analytical chemistry. 2006; 78(3):779–87. doi: 10.1021/ac051437y PMID: 16448051.

22. Kamburov A, Cavill R, Ebbels TM, Herwig R, Keun HC. Integrated pathway-level analysis of transcriptomics and metabolomics data with IMPaLA. Bioinformatics. 2011; 27(20):2917–8. doi: 10.1093/bioinformatics/btr499 PMID: 21893519.

23. Vinaixa M, Samino S, Saez I, Duran J, Guinovart JJ. A Guideline to Univariate Statistical Analysis for LC/MS-Based Untargeted Metabolomics-Derived Data. Metabolites. 2012; 2(4):775–95. Epub 2012/01/01. doi: 10.3390/metabo2040775 PMID: 24957762; PubMed Central PMCID: PMC3901240.

24. Kawashima Y, Fritton JC, Yakar S, Epstein S, Schaffler MB, Jepsen KJ, et al. Type 2 diabetic mice demonstrate slender long bones with increased fragility secondary to increased osteoclastogenesis. Bone. 2009; 44(4):648–55. Epub 2009/01/20. doi: 10.1016/j.bone.2008.12.012 PMID: 19150422; PubMed Central PMCID: PMC2659558.

25. Janzer A, German NJ, Gonzalez-Herrera KN, Asara JM, Haigis MC, Struhl K. Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells. Proceedings of the National Academy of Sciences of the United States of America. 2014; 111(29):10574–9. doi: 10.1073/pnas.1408944111 PMID: 25002509; PubMed Central PMCID: PMC4115496.

26. Large V, Beylot M. Modifications of citric acid cycle activity and gluconeogenesis in streptozotocin-induced diabetes and effects of metformin. Diabetes. 1999; 48(6):1251–7. PMID: 10342812.

27. Andrzejewski S, Gravel SP, Pollak M, St-Pierre J. Metformin directly acts on mitochondria to alter cellular bioenergetics. Cancer & metabolism. 2014; 2:12. Epub 2014/09/04. doi: 10.1186/2049-3002-2-12 PMID: 25184038; PubMed Central PMCID: PMC4147388.

28. Cheema AK, Timofeeva O, Varghese R, Dimtchev A, Shiekh K, Shulaev V, et al. Integrated analysis of ATM mediated gene and protein expression impacting cellular metabolism. Journal of proteome research. 2011; 10(5):2651–7. doi: 10.1021/pr101243j PMID: 21322649.

29. Hundal RS, Inzucchi SE. Metformin: new understandings, new uses. Drugs. 2003; 63(18):1879–94. PMID: 12930161.

30. Takarada T, Yoneda Y. Pharmacological topics of bone metabolism: glutamate as a signal mediator in bone. Journal of pharmacological sciences. 2008; 106(4):536–41. Epub 2008/04/24. PMID: 18431036.

31. Miranda VC, Barroso-Sousa R, Glasberg J, Riechelmann RP. Exploring the role of metformin in anti-cancer treatments: a systematic review. Drugs of today. 2014; 50(9):623–40. doi: 10.1358/dot.2014.50.9.2299926 PMID: 25313369.

32. Miller RA, Birnbaum MJ. An energetic tale of AMPK-independent effects of metformin. The Journal of clinical investigation. 2010; 120(7):2267–70. doi: 10.1172/JCI43661 PMID: 20577046; PubMed Central PMCID: PMC2898617.

33. Gravel SP, Hulea L, Toban N, Birman E, Blouin MJ, Zakikhani M, et al. Serine deprivation enhances antineoplastic activity of biguanides. Cancer research. 2014; 74(24):7521–33. doi: 10.1158/0008-5472.CAN-14-2643-T PMID: 25377470.

34. Kos E, Liszek MJ, Emanuele MA, Durazo-Arvizu R, Camacho P. Effect of metformin therapy on vitamin D and vitamin B(1)(2) levels in patients with type 2 diabetes mellitus. Endocrine practice: official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2012; 18(2):179–84. doi: 10.1093/epi201109.OR PMID: 21940283.

35. Corominas-Faja B, Quirantes-Pine R, Oliveras-Ferreros C, Vazquez-Martin A, Cufi S, Martin-Castillo B, et al. Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs. Aging. 2012; 4(7):480–98. PMID: 22837425; PubMed Central PMCID: PMC3433934.
39. Newsholme P, Brennan L, Rubi B, Maechler P. New insights into amino acid metabolism, beta-cell function and diabetes. Clinical science. 2005; 108(3):185–94. doi: 10.1042/CS20040290 PMID: 15544573.

40. Shambaugh GE 3rd. Urea biosynthesis I. The urea cycle and relationships to the citric acid cycle. The American journal of clinical nutrition. 1977; 30(12):2083–7. PMID: 337792.

41. Tagliaferri C, Salies J, Landrier JF, Giraudet C, Patrac V, Lebecque P, et al. Increased body fat mass and tissue lipotoxicity associated with ovariectomy or high-fat diet differentially affects bone and skeletal muscle metabolism in rats. European journal of nutrition. 2014. Epub 2014/11/06. doi: 10.1007/s00394-014-0790-0 PMID: 25370302.

42. Newton L, Hanks J, Davis M, Casazza K. The relationships among total body fat, bone mineral content and bone marrow adipose tissue in early-pubertal girls. BoneKEy reports. 2013; 2:315. Epub 2013/08/21. doi: 10.1038/bonekey.2013.49 PMID: 2395154; PubMed Central PMCID: PMC3722749.

43. Wu CL, Diekman BO, Jain D, Guilak F. Diet-induced obesity alters the differentiation potential of stem cells isolated from bone marrow, adipose tissue and infrapatellar fat pad: the effects of free fatty acids. Int J Obes (Lond). 2013; 37(8):1079–87. Epub 2012/11/21. doi: 10.1038/j.ijo.2012.171 PMID: 23164688; PubMed Central PMCID: PMC3582830.

44. Gore DC, Wolf SE, Sanford A, Herndon DN, Wolfe RR. Influence of metformin on glucose intolerance and muscle catabolism following severe burn injury. Annals of surgery. 2005; 241(2):334–42. PMID: 15650645; PubMed Central PMCID: PMC1356920.

45. Koenig W, Meisinger C. Uric acid, type 2 diabetes, and cardiovascular diseases: fueling the common soil hypothesis? Clinical chemistry. 2008; 54(2):231–3. doi: 10.1373/clinchem.2007.099705 PMID: 18223129.

46. Suilamia WR, Johnson RH. The effects of phenformin and metformin on fat and carbohydrate metabolism. Acta diabetologica latina. 1977; 14(3–4):129–36. Epub 1977/05/01. PMID: 605743.

47. Cowan RW, Seidlitz EP, Singh G. Glutamate signaling in healthy and diseased bone. Frontiers in endocrinology. 2012; 3:89. Epub 2012/07/27. doi: 10.3389/fendo.2012.00089 PMID: 22833735; PubMed Central PMCID: PMC3400067.

48. Uno K, Takarada T, Hinoi E, Yoneda Y. Glutamate is a determinant of cellular proliferation through the cystine/glutamate antiporter in mesenchymal stem cells. Journal of cellular physiology. 2011; 226(3):652–65. Epub 2010/08/19. doi: 10.1002/jcp.22390 PMID: 20717926.

49. Takarakela-mata M, Takarada T, Nakamura Y, Nakatani E, Hori O, Yoneda Y. Glutamate preferentially suppresses osteoblastogenesis than adipogenesis through the cystine/glutamate antiporter in mesenchymal stem cells. Journal of cellular physiology. 2011; 226(3):652–65. Epub 2010/08/19. doi: 10.1002/jcp.22390 PMID: 20717926.

50. Merle B, Itzstein C, Delmas PD, Chen C. NMDA glutamate receptors are expressed by osteoclast precursors and involved in the regulation of osteoclastogenesis. Journal of cellular biochemistry. 2003; 90 (2):424–36. Epub 2003/09/25. doi: 10.1002/jcb.10625 PMID: 14503597.

51. Tai ES, Tan ML, Stevens RD, Low YL, Muehlbauer MJ, Goh DL, et al. Insulin resistance is associated with a metabolic profile of altered protein metabolism in Chinese and Asian-Indian men. Diabetologia. 2010; 53(4):757–67. Epub 2010/01/16. doi: 10.1007/s00125-009-1637-8 PMID: 20076942; PubMed Central PMCID: PMC3753085.

52. Favret S, Binet F, Lapalme E, Leboeuf D, Carbadillo J, Rubic T, et al. Deficiency in the metabolite receptor SUCNR1 (GPR91) leads to outer retinal lesions. Aging. 2013; 5(6):427–76. Epub 2013/07/09. doi: 10.1189/jlb.1008618 PMID: 23833031; PubMed Central PMCID: PMC3832265.

53. Gnana-Prakasam JP, Ananth S, Prasad PD, Zhang M, Atherton SS, Martin PM, et al. Expression and iron-dependent regulation of succinate receptor GPR91 in retinal pigment epithelium. Investigative ophthalmology & visual science. 2011; 52(6):3751–8. Epub 2011/03/02. doi: 10.1096/iovs.10-6722 PMID: 21357408; PubMed Central PMCID: PMC3753085.

54. Hakal Y, Lehmann-Bruinsma K, Phillips S, Le T, Liaw C, Connolly DT, et al. The role of the GPR91 ligand succinate in hemopoiesis. Journal of leucocyte biology. 2009; 85(5):837–43. Epub 2009/02/11. doi: 10.1189/jlb.0509417.

55. Rubin T, Lametschwardnter G, Jost S, Hinteregger S, Kund J, Carballido-Perrig N, et al. Triggering the succinate receptor GPR91 on dendritic cells enhances immunity. Nature immunology. 2008; 9 (11):1261–9. Epub 2008/09/30. doi: 10.1038/ni.1657 PMID: 18820681.

56. Sapieha P, Sirinyan M, Hamel D, Zaniolo K, Joyal JS, Cho JH, et al. The succinate receptor GPR91 in neurons has a major role in retinal angiogenesis. Nature medicine. 2008; 14(10):1067–76. Epub 2008/10/07. doi: 10.1038/nm.1873 PMID: 18836459.

57. Chung YH, Choi B, Song DH, Song Y, Kang SW, Yoon SY, et al. Interleukin-1beta promotes the LC3-mediated secretory function of osteoclast precursors by stimulating the Ca(2+)-dependent activation of
ERK. The international journal of biochemistry & cell biology. 2014; 54:198–207. Epub 2014/08/06. doi: 10.1016/j.biocel.2014.07.018 PMID: 25091703.

58. Li H, Zhai Z, Liu G, Tang T, Lin Z, Zheng M, et al. Sanguinarine inhibits osteoclast formation and bone resorption via suppressing RANKL-induced activation of NF-kappaB and ERK signaling pathways. Biochemical and biophysical research communications. 2013; 430(3):951–6. Epub 2012/12/25. doi: 10.1016/j.bbrc.2012.12.051 PMID: 23261473.

59. Tsubaki M, Kato C, Isono A, Kaneko J, Isozaki M, Satou T, et al. Macrophage inflammatory protein-1alpha induces osteoclast formation by activation of the MEK/ERK/c-Fos pathway and inhibition of the p38MAPK/IRF-3/IFN-beta pathway. Journal of cellular biochemistry. 2010; 111(6):1661–72. Epub 2010/11/06. doi: 10.1002/jcb.22907 PMID: 21053363.

59. Tsubaki M, Kato C, Isono A, Kaneko J, Isozaki M, Satou T, et al. Macrophage inflammatory protein-1alpha induces osteoclast formation by activation of the MEK/ERK/c-Fos pathway and inhibition of the p38MAPK/IRF-3/IFN-beta pathway. Journal of cellular biochemistry. 2010; 111(6):1661–72. Epub 2010/11/06. doi: 10.1002/jcb.22907 PMID: 21053363.

59. Tsubaki M, Kato C, Isono A, Kaneko J, Isozaki M, Satou T, et al. Macrophage inflammatory protein-1alpha induces osteoclast formation by activation of the MEK/ERK/c-Fos pathway and inhibition of the p38MAPK/IRF-3/IFN-beta pathway. Journal of cellular biochemistry. 2010; 111(6):1661–72. Epub 2010/11/06. doi: 10.1002/jcb.22907 PMID: 21053363.

60. Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD, et al. Requirement for NF-kappaB in osteoclast and B-cell development. Genes & development. 1997; 11(24):3482–96. Epub 1998/02/07. PMID: 9407039; PubMed Central PMCID: PMC316809.

61. Jimi E, Aoki K, Saito H, D’Acquisto F, May MJ, Nakamura I, et al. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nature medicine. 2004; 10(6):617–24. Epub 2004/05/25. doi: 10.1038/nm1054 PMID: 15156202.

62. Tsubaki M, Komai M, Itoh T, Imano M, Sakamoto K, Shimaoka H, et al. Nitrogen-containing bisphosphonates inhibit RANKL- and M-CSF-induced osteoclast formation through the inhibition of ERK1/2 and Akt activation. Journal of biomedical science. 2014; 21:10. Epub 2014/02/05. doi: 10.1186/1423-0127-21-10 PMID: 24490900; PubMed Central PMCID: PMC3996180.

63. Mediero A, Perez-Aso M, Cronstein BN. Activation of adenosine A(2A) receptor reduces osteoclast formation via PKA- and ERK1/2-mediated suppression of NFkappaB nuclear translocation. British journal of pharmacology. 2013; 169(6):1372–88. Epub 2013/05/08. doi: 10.1111/bph.12227 PMID: 23647065; PubMed Central PMCID: PMC3831714.

64. Sundstrom L, Greasley PJ, Engberg S, Wallander M, Ryberg E. Succinate receptor GPR91, a Galpha (i) coupled receptor that increases intracellular calcium concentrations through PLCbeta. FEBS letters. 2013; 587(15):2399–404. Epub 2013/06/19. doi: 10.1016/j.febslet.2013.05.067 PMID: 23770096.

65. Kajiya H. Calcium signaling in osteoclast differentiation and bone resorption. Advances in experimental medicine and biology. 2012; 740:917–32. Epub 2012/03/29. doi: 10.1007/978-94-007-2888-2_41 PMID: 22453976.

66. Ang ES, Zhang P, Steer JH, Tan JW, Yip K, Zheng MH, et al. Calcium/calmodulin-dependent kinase activity is required for efficient induction of osteoclast differentiation and bone resorption by receptor activator of nuclear factor kappa B ligand (RANKL). Journal of cellular physiology. 2007; 212(3):787–95. Epub 2007/05/05. doi: 10.1002/jcp.21076 PMID: 17477372.

67. Miyachi A, Notoya K, Taketomi S, Takagi Y, Fujiy Y, Jinnai K, et al. Novel ipriflavone receptors coupled to calcium influx regulate osteoclast differentiation and function. Endocrinology. 1996; 137(8):3544–50. Epub 1996/08/01. doi: 10.1210/endo.137.8.8754785 PMID: 8754785.